Related Experiment Video

Updated: Feb 26, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

764

Central Nervous System Fungal Infection and Acute Lymphoblastic Leukemia in Children: What is the Optimal Duration of

Harsha P Lashkari1, Neil Fernandes, Kishan Alva

  • 1*KMC Hospitals, Manipal University †K S Hegde Medical College Academy, Nitte University, Mangalore, India.

Journal of Pediatric Hematology/Oncology
|July 22, 2017
PubMed

Insights

Central nervous system fungal infections are rare but dangerous in children undergoing acute lymphoblastic leukemia therapy. This case study shows successful management of Aspergillus CNS abscesses without interrupting leukemia treatment, highlighting the need for optimal antifungal therapy duration.

Area of Science:

  • Pediatric Oncology
  • Infectious Diseases
  • Hematology

Background:

  • Invasive fungal infections (IFIs) are uncommon in pediatric acute lymphoblastic leukemia (ALL) but significantly complicate treatment.
  • Central nervous system (CNS) fungal infections in this population are associated with high mortality rates.
  • Prompt diagnosis and management are crucial to prevent treatment delays and improve outcomes.

Observation:

  • A 6.5-year-old girl with ALL developed multiple CNS fungal abscesses during induction chemotherapy, suspected to be Aspergillus.
  • The patient was managed with concurrent antifungal therapy and maintenance chemotherapy, avoiding interruption of her leukemia treatment.
  • Treatment duration for antifungal therapy in similar cases varies widely, ranging from 4 to 24 months.

Findings:

  • Successful management of CNS fungal abscesses in a pediatric ALL patient was achieved without compromising essential antileukemia therapy.
  • The patient received a total of 20 months of antifungal therapy and maintenance chemotherapy.
  • Literature review indicates a broad range in optimal antifungal therapy duration for such complex cases.

Implications:

  • This case demonstrates that aggressive antifungal treatment can be safely integrated with chemotherapy for pediatric ALL patients with CNS fungal infections.
  • Effective management strategies can prevent delays in leukemia treatment, potentially improving survival rates.
  • Further research is warranted to establish standardized guidelines for the optimal duration of antifungal therapy in pediatric ALL with CNS fungal infections.

More Related Videos

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract07:42

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract

Published on: July 1, 2020

5.9K
Modeling Chemotherapy Resistant Leukemia In Vitro08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
332
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
377
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
377